PHI with Cerebral arteritis
How does this condition affect your private health insurance?
Zerebrale Arteriitis, also known as cerebral vasculitis, is a rare and severe inflammatory disorder affecting blood vessels within the brain. This inflammation can cause vessel narrowing, occlusion, or rupture, leading to reduced blood flow, ischemia, hemorrhage, or stroke. It can be a primary condition affecting only the central nervous system or secondary to systemic autoimmune diseases like lupus or granulomatosis with polyangiitis. Symptoms are varied and often non-specific, including severe headaches, seizures, cognitive changes, and focal neurological deficits. Early diagnosis, often challenging, relies on advanced imaging, cerebrospinal fluid analysis, and sometimes biopsy. Treatment typically involves corticosteroids and immunosuppressants to prevent irreversible brain damage.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often requiring hospitalization for diagnosis and acute management.
Duration of Illness (Lifetime)
Chronic, often requiring long-term immunosuppressive therapy and prone to relapses over a lifetime.
Cost of Treatment (Initial)
High, often exceeding $50,000, including hospitalization, advanced imaging (MRI, MRA, DSA), lumbar puncture, and initial high-dose immunosuppressive therapy.
Cost of Treatment (Lifetime)
Very high, potentially hundreds of thousands to millions of USD over a lifetime, encompassing chronic medication, regular monitoring, and management of sequelae and relapses.
Mortality Rate
Moderate to high (10-30%), especially if diagnosis is delayed, in severe cases, or due to complications of treatment.
Risk of Secondary Damages
High (50-80%), including permanent neurological deficits such as stroke, cognitive impairment, seizures, visual deficits, and psychiatric issues.
Probability of Full Recovery
Low (less than 20%), as residual neurological or cognitive deficits are common even with effective treatment.
Underlying Disease Risk
Moderate to high (30-60%), as it can be secondary to systemic autoimmune diseases like Systemic Lupus Erythematosus (SLE), Granulomatosis with Polyangiitis (GPA), or Giant Cell Arteritis, or present as primary CNS vasculitis.